The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma

The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target

(2010) Jan-Bart M. Koorstra et al.   CANCER BIOLOGY & THERAPY

R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer

(2010) S. J. Holland et al.   CANCER RESEARCH

Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

(2009) L. Liu et al.   CANCER RESEARCH

Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy

(2009) J. Veeken et al.   CURRENT CANCER DRUG TARGETS

Preoperative Therapy for Esophageal Cancer

(2009) Geoffrey Y. Ku et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Screening, Surveillance, and Prevention for Esophageal Cancer

(2009) Yutaka Tomizawa et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Cancer Genomes on a Shoestring Budget

(2009) Jay Shendure et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis

(2009) Y Li et al.   ONCOGENE

Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival

(2009) C. Gjerdrum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia

(2008) Chih-Chen Hong et al.   CANCER LETTERS

Esophageal adenocarcinoma arising in Barrett esophagus

(2008) Hui Ying Zhang et al.   CANCER LETTERS

AXL Is a Potential Target for Therapeutic Intervention in Breast Cancer Progression

(2008) Y.-X. Zhang et al.   CANCER RESEARCH

The ErbB kinase domain: Structural perspectives into kinase activation and inhibition

(2008) Ron Bose et al.   EXPERIMENTAL CELL RESEARCH

Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy

(2008) Hector Alvarez et al.   Nanomedicine-Nanotechnology Biology and Medicine